ERBB2 and neoplasm: In the trastuzumab plus lapatinib-resistant HER2-PDX model EGCG treatment decreased the median tumor growth (231.8 ± 38.4 mm3) compared with control group (314.8 ± 81.1 mm3) at the end of the experiment (Fig 5A, left panel).